Prelude Therapeutics Inc. (PRLD): Price and Financial Metrics

Prelude Therapeutics Inc. (PRLD): $5.79

0.26 (+4.70%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

D

Add PRLD to Watchlist
Sign Up

Industry: Medical - Pharmaceuticals

Industry

D

Ranked

#120 of 167

in industry

PRLD Price/Volume Stats

Current price $5.79 52-week high $8.90
Prev. close $5.53 52-week low $4.16
Day low $5.62 Volume 106,000
Day high $5.85 Avg. volume 85,829
50-day MA $6.34 Dividend yield N/A
200-day MA $6.50 Market Cap 277.66M

PRLD Stock Price Chart Interactive Chart >


Prelude Therapeutics Inc. (PRLD) Company Bio


Prelude Therapeutics, Inc. operates as a cancer drug discovery company. It focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Gopi Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.


PRLD Latest News Stream


Event/Time News Detail
Loading, please wait...

PRLD Latest Social Stream


Loading social stream, please wait...

View Full PRLD Social Stream

Latest PRLD News From Around the Web

Below are the latest news stories about PRELUDE THERAPEUTICS INC that investors may wish to consider to help them evaluate PRLD as an investment opportunity.

Prelude Therapeutics Announces Pricing of Public Offering

WILMINGTON, Del., May 18, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated ("Prelude" or the "Company") (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the pricing of its underwritten public offering of 3,048,522 shares of its voting common stock and 1,448,222 shares of its non-voting common stock, each at a price to the public of $5.75 per share, and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase up to an aggregate of

Yahoo | May 18, 2023

Prelude Therapeutics Announces Launch of Proposed Public Offering

WILMINGTON, Del., May 17, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude” or the “Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that it has commenced an underwritten public offering of $100.0 million of shares of common stock and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase shares of common stock. All of the shares of common stock and pre-funded warrants are being offered by Prelude. In additi

Yahoo | May 17, 2023

Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update

Eight abstracts presented at AACR 2023 demonstrate progress of the pipeline Cash runway unchanged, supporting operations into the fourth quarter of 2024 WILMINGTON, Del., May 08, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2023, and provided an update on recent clinical and development pipeline progress. “Our recent presentations at the 2023 AACR Annu

Yahoo | May 8, 2023

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May

WILMINGTON, Del., April 27, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will participate in three upcoming healthcare investment conferences. Details are as follows: H. C. Wainwright BioConnect Investor Conference at Nasdaq Kris Vaddi, Ph.D., Chief Executive Officer will participate in a fireside chat on Tuesday, May 2, at 1:30 p.m. ET. The live webcast is available here. The Compa

Yahoo | April 27, 2023

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference

Eight Abstracts Demonstrate Progress of Prelude’s Differentiated PipelineWILMINGTON, Del., April 11, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced details relating to eight abstracts being presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida. “Prelude's six preclinical and two clinical abstracts being presented at the AACR Annual

Yahoo | April 11, 2023

Read More 'PRLD' Stories Here

PRLD Price Returns

1-mo -6.01%
3-mo -0.17%
6-mo -18.34%
1-year 37.86%
3-year N/A
5-year N/A
YTD -4.14%
2022 -51.49%
2021 -82.60%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!